Concepts (345)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 24 | 2023 | 123 | 8.610 |
Why?
|
| Blood Glucose | 27 | 2023 | 309 | 4.570 |
Why?
|
| Exercise | 18 | 2023 | 479 | 3.270 |
Why?
|
| Insulin Resistance | 5 | 2022 | 175 | 2.800 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2023 | 332 | 2.540 |
Why?
|
| Postprandial Period | 9 | 2022 | 44 | 2.010 |
Why?
|
| Hypoglycemic Agents | 10 | 2022 | 108 | 2.010 |
Why?
|
| Insulin | 13 | 2022 | 322 | 1.950 |
Why?
|
| Thrombosis | 3 | 2022 | 149 | 1.930 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2021 | 39 | 1.890 |
Why?
|
| Hypoglycemia | 9 | 2022 | 34 | 1.890 |
Why?
|
| Insulin, Short-Acting | 4 | 2021 | 4 | 1.460 |
Why?
|
| Dietary Fats | 3 | 2022 | 59 | 1.410 |
Why?
|
| Cardiovascular Diseases | 3 | 2021 | 366 | 1.360 |
Why?
|
| Glycated Hemoglobin A | 11 | 2022 | 64 | 1.290 |
Why?
|
| Oligopeptides | 5 | 2021 | 97 | 1.180 |
Why?
|
| Dietary Supplements | 4 | 2020 | 254 | 1.170 |
Why?
|
| Diet, High-Fat | 2 | 2021 | 137 | 1.150 |
Why?
|
| Meals | 4 | 2020 | 22 | 1.130 |
Why?
|
| Humans | 53 | 2023 | 28100 | 1.110 |
Why?
|
| Mitochondria | 7 | 2023 | 371 | 1.090 |
Why?
|
| Inflammation Mediators | 4 | 2021 | 165 | 1.040 |
Why?
|
| Biomarkers | 10 | 2022 | 765 | 1.040 |
Why?
|
| Adult | 27 | 2022 | 7739 | 1.030 |
Why?
|
| Muscle, Skeletal | 6 | 2023 | 634 | 1.010 |
Why?
|
| Male | 35 | 2022 | 13495 | 0.960 |
Why?
|
| Blood Coagulation | 3 | 2021 | 118 | 0.940 |
Why?
|
| Aging | 8 | 2023 | 968 | 0.920 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2021 | 20 | 0.890 |
Why?
|
| Dietary Carbohydrates | 4 | 2017 | 26 | 0.880 |
Why?
|
| Fibrinogen | 2 | 2021 | 50 | 0.870 |
Why?
|
| Prediabetic State | 2 | 2020 | 10 | 0.820 |
Why?
|
| Hyperglycemia | 8 | 2020 | 78 | 0.820 |
Why?
|
| Precision Medicine | 2 | 2020 | 76 | 0.750 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 215 | 0.740 |
Why?
|
| Female | 27 | 2023 | 15156 | 0.740 |
Why?
|
| Insulin Glargine | 5 | 2017 | 6 | 0.740 |
Why?
|
| Metabolic Syndrome | 2 | 2023 | 79 | 0.730 |
Why?
|
| Lipid Droplets | 1 | 2021 | 8 | 0.720 |
Why?
|
| Thromboplastin | 1 | 2021 | 28 | 0.700 |
Why?
|
| Hepatitis C | 1 | 2021 | 40 | 0.680 |
Why?
|
| Bifidobacterium | 1 | 2020 | 2 | 0.680 |
Why?
|
| Time Factors | 9 | 2021 | 1594 | 0.680 |
Why?
|
| Life Style | 2 | 2023 | 89 | 0.670 |
Why?
|
| Abdominal Pain | 1 | 2020 | 35 | 0.670 |
Why?
|
| Probiotics | 1 | 2020 | 18 | 0.660 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2020 | 32 | 0.660 |
Why?
|
| Glucose | 5 | 2022 | 206 | 0.650 |
Why?
|
| Running | 3 | 2015 | 39 | 0.650 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 46 | 0.640 |
Why?
|
| Physical Conditioning, Animal | 2 | 2018 | 38 | 0.630 |
Why?
|
| Hemodynamics | 1 | 2020 | 220 | 0.620 |
Why?
|
| Treatment Outcome | 7 | 2022 | 2378 | 0.610 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 27 | 0.600 |
Why?
|
| Oxidative Stress | 3 | 2023 | 668 | 0.590 |
Why?
|
| Diabetic Angiopathies | 1 | 2018 | 48 | 0.580 |
Why?
|
| Glycemic Index | 2 | 2014 | 5 | 0.570 |
Why?
|
| Insulin Detemir | 2 | 2017 | 2 | 0.570 |
Why?
|
| Energy Metabolism | 3 | 2020 | 204 | 0.570 |
Why?
|
| Microvessels | 1 | 2018 | 86 | 0.560 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 82 | 0.560 |
Why?
|
| Inflammation | 3 | 2021 | 636 | 0.560 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2018 | 12 | 0.560 |
Why?
|
| Risk Factors | 7 | 2023 | 2081 | 0.560 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 143 | 0.560 |
Why?
|
| Long QT Syndrome | 1 | 2018 | 13 | 0.560 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2018 | 28 | 0.560 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2023 | 385 | 0.560 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 45 | 0.550 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 163 | 0.550 |
Why?
|
| Electrocardiography | 2 | 2019 | 394 | 0.530 |
Why?
|
| Myocytes, Cardiac | 2 | 2016 | 62 | 0.510 |
Why?
|
| England | 4 | 2021 | 39 | 0.510 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 93 | 0.510 |
Why?
|
| Heart Conduction System | 1 | 2018 | 270 | 0.510 |
Why?
|
| Young Adult | 9 | 2022 | 2733 | 0.510 |
Why?
|
| Exercise Therapy | 2 | 2014 | 84 | 0.500 |
Why?
|
| Sarcoglycans | 1 | 2016 | 3 | 0.500 |
Why?
|
| Genes, Dominant | 1 | 2016 | 35 | 0.500 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2016 | 19 | 0.490 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2016 | 26 | 0.490 |
Why?
|
| Diet, Diabetic | 2 | 2014 | 4 | 0.490 |
Why?
|
| Endothelial Progenitor Cells | 3 | 2022 | 6 | 0.490 |
Why?
|
| Mitochondria, Muscle | 1 | 2015 | 43 | 0.480 |
Why?
|
| Appetite | 4 | 2022 | 19 | 0.480 |
Why?
|
| Molecular Imaging | 1 | 2015 | 35 | 0.470 |
Why?
|
| Sharks | 1 | 2015 | 7 | 0.470 |
Why?
|
| Appetite Regulation | 1 | 2014 | 2 | 0.460 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 180 | 0.460 |
Why?
|
| Stress, Physiological | 1 | 2015 | 96 | 0.440 |
Why?
|
| Snacks | 1 | 2014 | 5 | 0.440 |
Why?
|
| Games, Recreational | 1 | 2014 | 3 | 0.430 |
Why?
|
| Animals | 19 | 2025 | 10440 | 0.430 |
Why?
|
| Mutation | 2 | 2023 | 844 | 0.410 |
Why?
|
| Fishes | 2 | 2025 | 32 | 0.400 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 962 | 0.390 |
Why?
|
| Middle Aged | 9 | 2022 | 7137 | 0.390 |
Why?
|
| Resistance Training | 4 | 2015 | 212 | 0.380 |
Why?
|
| DNA, Mitochondrial | 2 | 2023 | 82 | 0.370 |
Why?
|
| Diabetes, Gestational | 2 | 2023 | 68 | 0.370 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2017 | 247 | 0.330 |
Why?
|
| Cross-Over Studies | 5 | 2022 | 134 | 0.320 |
Why?
|
| Mice | 11 | 2023 | 4659 | 0.290 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2021 | 102 | 0.290 |
Why?
|
| Blood Pressure | 2 | 2020 | 354 | 0.290 |
Why?
|
| Blood Glucose Self-Monitoring | 3 | 2023 | 21 | 0.280 |
Why?
|
| Physical Fitness | 3 | 2017 | 62 | 0.280 |
Why?
|
| Breakfast | 2 | 2018 | 5 | 0.270 |
Why?
|
| Whey Proteins | 2 | 2018 | 13 | 0.270 |
Why?
|
| Lunch | 2 | 2018 | 10 | 0.270 |
Why?
|
| Phenotype | 2 | 2020 | 677 | 0.240 |
Why?
|
| Insulin Aspart | 2 | 2015 | 2 | 0.240 |
Why?
|
| Prospective Studies | 2 | 2018 | 1247 | 0.220 |
Why?
|
| Interleukin-6 | 3 | 2015 | 194 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 1578 | 0.220 |
Why?
|
| Adolescent | 4 | 2022 | 3122 | 0.220 |
Why?
|
| Oxidation-Reduction | 3 | 2021 | 366 | 0.220 |
Why?
|
| Lactic Acid | 2 | 2015 | 94 | 0.210 |
Why?
|
| Family Health | 1 | 2023 | 71 | 0.210 |
Why?
|
| Dietary Proteins | 1 | 2022 | 35 | 0.200 |
Why?
|
| Metformin | 1 | 2023 | 36 | 0.200 |
Why?
|
| Hyperkalemia | 1 | 2022 | 8 | 0.190 |
Why?
|
| Dinoflagellida | 1 | 2022 | 2 | 0.190 |
Why?
|
| Combined Modality Therapy | 4 | 2016 | 300 | 0.190 |
Why?
|
| Satiety Response | 1 | 2022 | 1 | 0.190 |
Why?
|
| Cicer | 1 | 2022 | 1 | 0.190 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2022 | 8 | 0.190 |
Why?
|
| Oxygen Consumption | 3 | 2021 | 181 | 0.190 |
Why?
|
| Mutation Accumulation | 1 | 2021 | 1 | 0.190 |
Why?
|
| Food Handling | 1 | 2022 | 17 | 0.190 |
Why?
|
| Body Mass Index | 2 | 2021 | 399 | 0.190 |
Why?
|
| Child | 2 | 2018 | 2242 | 0.180 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 30 | 0.180 |
Why?
|
| Receptors, CXCR | 1 | 2021 | 1 | 0.180 |
Why?
|
| Genome, Mitochondrial | 1 | 2021 | 16 | 0.180 |
Why?
|
| Injections, Subcutaneous | 1 | 2021 | 60 | 0.180 |
Why?
|
| Linoleic Acids | 1 | 2021 | 2 | 0.180 |
Why?
|
| Double-Blind Method | 2 | 2020 | 417 | 0.180 |
Why?
|
| Erythrocyte Membrane | 1 | 2021 | 23 | 0.180 |
Why?
|
| DNA Replication | 1 | 2021 | 51 | 0.180 |
Why?
|
| Proteomics | 1 | 2023 | 181 | 0.180 |
Why?
|
| Triglycerides | 2 | 2023 | 121 | 0.180 |
Why?
|
| Muscle Proteins | 1 | 2021 | 56 | 0.180 |
Why?
|
| Coral Reefs | 1 | 2021 | 1 | 0.180 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 29 | 0.180 |
Why?
|
| Particle Size | 1 | 2021 | 101 | 0.170 |
Why?
|
| Platelet Aggregation | 1 | 2021 | 44 | 0.170 |
Why?
|
| Cluster Analysis | 1 | 2021 | 125 | 0.170 |
Why?
|
| Hepacivirus | 1 | 2021 | 48 | 0.170 |
Why?
|
| Insulin, Long-Acting | 3 | 2014 | 4 | 0.170 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2021 | 98 | 0.170 |
Why?
|
| Aged | 5 | 2023 | 5399 | 0.170 |
Why?
|
| Canada | 1 | 2020 | 60 | 0.170 |
Why?
|
| Environmental Monitoring | 1 | 2021 | 66 | 0.170 |
Why?
|
| Machine Learning | 1 | 2021 | 84 | 0.170 |
Why?
|
| Telemedicine | 1 | 2023 | 174 | 0.170 |
Why?
|
| Mitochondria, Heart | 1 | 2020 | 23 | 0.170 |
Why?
|
| Glucose Intolerance | 1 | 2020 | 24 | 0.160 |
Why?
|
| Adenosine Triphosphate | 2 | 2021 | 120 | 0.160 |
Why?
|
| Heart Diseases | 1 | 2020 | 71 | 0.160 |
Why?
|
| Fatty Acids | 1 | 2021 | 206 | 0.160 |
Why?
|
| Retrospective Studies | 3 | 2023 | 2543 | 0.160 |
Why?
|
| Lipids | 2 | 2018 | 208 | 0.160 |
Why?
|
| Vasodilation | 1 | 2020 | 114 | 0.160 |
Why?
|
| Collagen Type IV | 2 | 2017 | 6 | 0.160 |
Why?
|
| Europe, Eastern | 1 | 2019 | 1 | 0.160 |
Why?
|
| Croatia | 1 | 2019 | 1 | 0.160 |
Why?
|
| Slovenia | 1 | 2019 | 1 | 0.160 |
Why?
|
| Bulgaria | 1 | 2019 | 2 | 0.160 |
Why?
|
| Hungary | 1 | 2019 | 5 | 0.160 |
Why?
|
| Greece | 1 | 2019 | 3 | 0.160 |
Why?
|
| Drug Overdose | 1 | 2019 | 11 | 0.150 |
Why?
|
| Bradycardia | 1 | 2019 | 17 | 0.150 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 29 | 0.150 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 34 | 0.150 |
Why?
|
| Finland | 1 | 2018 | 4 | 0.150 |
Why?
|
| Cytokines | 2 | 2018 | 447 | 0.150 |
Why?
|
| Risk Assessment | 1 | 2021 | 612 | 0.150 |
Why?
|
| Adolescent Behavior | 1 | 2019 | 68 | 0.150 |
Why?
|
| Glutathione | 1 | 2018 | 76 | 0.150 |
Why?
|
| Protective Factors | 1 | 2018 | 16 | 0.150 |
Why?
|
| Mitochondrial Proteins | 1 | 2018 | 74 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2019 | 95 | 0.140 |
Why?
|
| British Columbia | 1 | 2018 | 6 | 0.140 |
Why?
|
| Physical Endurance | 1 | 2018 | 91 | 0.140 |
Why?
|
| Germany | 1 | 2018 | 24 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 89 | 0.140 |
Why?
|
| Retina | 1 | 2021 | 436 | 0.140 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2016 | 551 | 0.140 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 208 | 0.140 |
Why?
|
| Decision Making | 1 | 2019 | 175 | 0.140 |
Why?
|
| Patient Selection | 1 | 2018 | 148 | 0.130 |
Why?
|
| Kidney Glomerulus | 1 | 2017 | 15 | 0.130 |
Why?
|
| Diabetic Retinopathy | 1 | 2018 | 110 | 0.130 |
Why?
|
| Walking | 1 | 2018 | 135 | 0.130 |
Why?
|
| Quality of Life | 1 | 2021 | 487 | 0.130 |
Why?
|
| Poly ADP Ribosylation | 1 | 2016 | 2 | 0.130 |
Why?
|
| Muscular Dystrophies | 1 | 2016 | 4 | 0.130 |
Why?
|
| Survival Rate | 1 | 2018 | 429 | 0.130 |
Why?
|
| Muscle Strength | 1 | 2018 | 230 | 0.130 |
Why?
|
| Lipid Metabolism | 2 | 2015 | 133 | 0.130 |
Why?
|
| Faecalibacterium | 1 | 2016 | 3 | 0.130 |
Why?
|
| Ecosystem | 3 | 2025 | 225 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 474 | 0.130 |
Why?
|
| Dysbiosis | 1 | 2016 | 15 | 0.130 |
Why?
|
| Bacteroides | 1 | 2016 | 15 | 0.130 |
Why?
|
| Clostridiales | 1 | 2016 | 6 | 0.130 |
Why?
|
| Age Factors | 1 | 2018 | 734 | 0.130 |
Why?
|
| Basement Membrane | 1 | 2016 | 6 | 0.120 |
Why?
|
| Laminin | 1 | 2016 | 21 | 0.120 |
Why?
|
| Myocardial Contraction | 1 | 2016 | 62 | 0.120 |
Why?
|
| Incidence | 1 | 2018 | 562 | 0.120 |
Why?
|
| Glycosylation | 1 | 2016 | 70 | 0.120 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 44 | 0.120 |
Why?
|
| NAD | 1 | 2016 | 103 | 0.120 |
Why?
|
| Endothelial Cells | 2 | 2017 | 351 | 0.120 |
Why?
|
| Drug Dosage Calculations | 1 | 2015 | 4 | 0.120 |
Why?
|
| Hordeum | 1 | 2015 | 1 | 0.120 |
Why?
|
| Protein Transport | 1 | 2016 | 158 | 0.120 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 115 | 0.120 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 25 | 0.120 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 73 | 0.120 |
Why?
|
| Transfection | 1 | 2016 | 318 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 971 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1013 | 0.120 |
Why?
|
| Jogging | 1 | 2014 | 2 | 0.120 |
Why?
|
| Glucagon | 1 | 2014 | 11 | 0.120 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2014 | 5 | 0.110 |
Why?
|
| Dietary Fiber | 1 | 2014 | 6 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 145 | 0.110 |
Why?
|
| Calcium, Dietary | 1 | 2014 | 11 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 123 | 0.110 |
Why?
|
| Cell Membrane | 1 | 2016 | 259 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2018 | 1146 | 0.110 |
Why?
|
| Carbohydrate Metabolism | 1 | 2014 | 29 | 0.110 |
Why?
|
| Random Allocation | 1 | 2014 | 151 | 0.110 |
Why?
|
| Rest | 1 | 2014 | 94 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2016 | 988 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2014 | 246 | 0.100 |
Why?
|
| Oviparity | 1 | 2013 | 1 | 0.100 |
Why?
|
| Exercise Test | 1 | 2014 | 248 | 0.100 |
Why?
|
| Heart Failure | 1 | 2016 | 249 | 0.100 |
Why?
|
| Calcium | 1 | 2014 | 239 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 666 | 0.100 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2013 | 24 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 608 | 0.100 |
Why?
|
| Reproduction | 1 | 2013 | 63 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 325 | 0.100 |
Why?
|
| Sleep | 1 | 2013 | 108 | 0.100 |
Why?
|
| United States | 1 | 2018 | 2145 | 0.090 |
Why?
|
| Diet | 2 | 2023 | 232 | 0.090 |
Why?
|
| Heart Rate | 2 | 2021 | 379 | 0.080 |
Why?
|
| Pregnancy | 2 | 2023 | 1190 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2021 | 433 | 0.070 |
Why?
|
| Risk | 2 | 2016 | 137 | 0.060 |
Why?
|
| Norepinephrine | 2 | 2015 | 32 | 0.060 |
Why?
|
| Epinephrine | 2 | 2015 | 37 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 451 | 0.050 |
Why?
|
| Electron Transport Complex I | 1 | 2023 | 13 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2016 | 885 | 0.050 |
Why?
|
| Postmenopause | 1 | 2023 | 83 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 42 | 0.050 |
Why?
|
| Harmful Algal Bloom | 1 | 2022 | 7 | 0.050 |
Why?
|
| Florida | 1 | 2022 | 54 | 0.050 |
Why?
|
| Algorithms | 1 | 2025 | 430 | 0.050 |
Why?
|
| DNA Polymerase gamma | 1 | 2021 | 1 | 0.050 |
Why?
|
| Flicker Fusion | 1 | 2021 | 1 | 0.050 |
Why?
|
| Color Vision | 1 | 2021 | 3 | 0.050 |
Why?
|
| Mutation Rate | 1 | 2021 | 6 | 0.050 |
Why?
|
| Night Vision | 1 | 2021 | 7 | 0.050 |
Why?
|
| Genetic Speciation | 1 | 2021 | 11 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2021 | 29 | 0.050 |
Why?
|
| Glutamine | 1 | 2021 | 32 | 0.050 |
Why?
|
| Photic Stimulation | 1 | 2021 | 67 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2021 | 128 | 0.050 |
Why?
|
| Bicycling | 1 | 2021 | 41 | 0.040 |
Why?
|
| Gulf of Mexico | 1 | 2021 | 2 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 189 | 0.040 |
Why?
|
| Animal Distribution | 1 | 2021 | 10 | 0.040 |
Why?
|
| Water | 1 | 2022 | 135 | 0.040 |
Why?
|
| Hypoxia | 1 | 2022 | 89 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2021 | 56 | 0.040 |
Why?
|
| Population Density | 1 | 2021 | 21 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 120 | 0.040 |
Why?
|
| Light | 1 | 2021 | 118 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2021 | 59 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 109 | 0.040 |
Why?
|
| Body Size | 1 | 2021 | 37 | 0.040 |
Why?
|
| Electroretinography | 1 | 2021 | 179 | 0.040 |
Why?
|
| Metabolomics | 1 | 2021 | 85 | 0.040 |
Why?
|
| Heart | 1 | 2021 | 223 | 0.040 |
Why?
|
| Biodiversity | 1 | 2021 | 112 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2020 | 40 | 0.040 |
Why?
|
| Models, Chemical | 1 | 2020 | 90 | 0.040 |
Why?
|
| Marijuana Abuse | 1 | 2019 | 14 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 542 | 0.040 |
Why?
|
| Xanthophylls | 1 | 2018 | 2 | 0.040 |
Why?
|
| Protein Binding | 1 | 2020 | 658 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 44 | 0.040 |
Why?
|
| Desmin | 1 | 2017 | 2 | 0.030 |
Why?
|
| Sclerosis | 1 | 2017 | 3 | 0.030 |
Why?
|
| Obesity | 1 | 2023 | 669 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 23 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 22 | 0.030 |
Why?
|
| Podocytes | 1 | 2017 | 11 | 0.030 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2016 | 3 | 0.030 |
Why?
|
| Tyramine | 1 | 2016 | 3 | 0.030 |
Why?
|
| Nitrosamines | 1 | 2016 | 5 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2016 | 27 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 31 | 0.030 |
Why?
|
| Muscular Diseases | 1 | 2016 | 12 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2017 | 82 | 0.030 |
Why?
|
| Actins | 1 | 2017 | 96 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2016 | 61 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 28 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 133 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 50 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 463 | 0.030 |
Why?
|
| Feces | 1 | 2016 | 109 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 76 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2015 | 36 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2017 | 247 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 224 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 506 | 0.030 |
Why?
|
| Myocardium | 1 | 2016 | 192 | 0.030 |
Why?
|
| Cell Line | 1 | 2016 | 696 | 0.030 |
Why?
|
| Growth Hormone | 1 | 2015 | 103 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2016 | 659 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 290 | 0.030 |
Why?
|
| Human Growth Hormone | 1 | 2014 | 15 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 722 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 819 | 0.030 |
Why?
|
| Phylogeny | 1 | 2016 | 479 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2014 | 89 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 2020 | 0.030 |
Why?
|
| Maine | 1 | 2013 | 1 | 0.030 |
Why?
|
| Oceans and Seas | 1 | 2013 | 6 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2013 | 45 | 0.030 |
Why?
|
| Seasons | 1 | 2013 | 89 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 632 | 0.020 |
Why?
|
| Rats | 1 | 2016 | 1581 | 0.020 |
Why?
|
| Progesterone | 1 | 2013 | 129 | 0.020 |
Why?
|
| Estradiol | 1 | 2013 | 175 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 391 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1460 | 0.020 |
Why?
|